How Much Is an Independent Pharmacy Worth?

How pharmacies are priced

Normalize the earnings, then apply a multiple that reflects risk, then add inventory at cost. The normalizing step in pharmacy has one dominant adjustment: cost in a market-rate pharmacist for every hour the owner stands behind the counter. An owner-pharmacist working full time is producing labor a buyer will have to pay for, and if that is not expensed, the reported SDE overstates the business by an entire pharmacist salary. Do that arithmetic first — in this category it frequently moves the price more than the multiple negotiation does.

The general mechanics — what qualifies as an add-back, how SDE differs from EBITDA, how working capital is handled at close — are covered in how to value a business. Below is what is specific to pharmacy.

The three numbers that set the multiple

• Script count — prescriptions filled per day, tracked monthly across at least three years. It is the closest thing to a clean unit-volume figure and it is far harder to dress up than revenue. Flat-to-growing supports the top of the range; a declining trend caps the deal near the bottom no matter what the last twelve months show.
• Gross profit per script — what the store keeps after drug cost and payer fees. This is the metric buyers most often fail to pull, and it is the one that reveals a store where revenue is rising while the business is quietly shrinking.
• Payer and product mix — government plans, commercial plans, cash customers, long-term-care work, and compounding all pay differently. A store weighted toward the worst-terms plans is structurally less profitable regardless of how well it is operated, and the buyer inherits that mix.

What else moves the multiple

• Profit earned off the dispensing counter — immunizations, point-of-care testing, medication synchronization and adherence packaging, durable medical equipment, compounding, and front-end retail. Revenue the store sets its own price on is worth more multiple than revenue a payer sets the price on.
• Who the customers are loyal to — a store where patients stay because of location, delivery, and adherence programs transfers cleanly. A store where they stay because of the retiring pharmacist personally does not, and the multiple should reflect it.
• Competitive position — a big-box or mail-order alternative opening nearby, or a health plan converting members to mail-order, changes the underwriting materially. Check what has opened in the trade area in the last two years.
• Lease and location — proximity to prescribing clinics is the demand driver in most independents. A short remaining lease term next to a medical office building is a real risk, not a formality.
• Systems and staff — a tenured technician team and a pharmacy management system the buyer can actually run reduce transition risk; both support the upper half of the range.

What pulls the price down

These are the findings that most often reprice a pharmacy deal between the letter of intent and the closing table. Each is a reason to bid below the mid-range, or to shift part of the price into a seller note or an earnout rather than paying it at close.

• An owner-pharmacist working full time with none of that labor expensed in the stated earnings.
• Script counts declining over two or more years, especially when the cause — a retiring prescriber, a lost facility contract, a plan's mail-order conversion — is not reversible by a new owner.
• Gross profit per script trending down while revenue holds flat.
• A few prescribers, one facility, or one employer plan producing most of the volume.
• Profit concentrated in a single drug or drug category whose reimbursement can be repriced by a payer at any time.
• Inventory that includes significant expired, slow-moving, or dead stock the seller expects to be paid for at cost.
• An asset-purchase structure where provider numbers and payer contracts cannot be re-credentialed before closing, creating a period when the store cannot bill.

Worked example: a $240,000 SDE single-store independent

A single-store independent reports $4.1M of revenue and $240,000 of SDE, and holds roughly $210,000 of inventory at cost. The owner is the full-time pharmacist-in-charge and has not expensed that role; a replacement pharmacist costs about $140,000 fully loaded, so normalized earnings are closer to $100,000. At a mid-range 3x, the goodwill component is roughly $300,000 — and inventory is added on top, bringing the indicative price near $510,000. Now adjust: script count has been flat for three years and gross profit per script has held (neutral to up), immunizations and adherence packaging contribute a meaningful share of profit (up), but one long-term-care facility drives about 30% of volume on a contract that does not automatically assign (down), and a physical count identifies $18,000 of expired and dead stock (down, dollar for dollar). A realistic bid lands near $460,000–$500,000 including verified inventory, with the facility contract's assignment made a closing condition and part of the price placed in a seller note tied to retaining it.

Run the same arithmetic on any listing you are considering. Restate earnings with a market-rate pharmacist paid, price the goodwill off that number, add only inventory that a count confirms is sellable, and then ask what in this specific store justifies its position in the range. If the answer relies on the revenue figure, you are being shown the number that matters least.

Before you rely on any of this

Market ranges orient a first conversation; they do not price a deal. Once you are past the initial screen, get three years of tax returns and reconcile them to the pharmacy management system rather than to the broker's summary — you want script counts by month, gross profit per script, and a payer-mix breakdown pulled from the system itself. Confirm your state board of pharmacy's ownership requirement in writing before you structure an offer, and settle the asset-versus-stock question with a healthcare attorney and the payers early, because the tax-efficient structure and the operationally continuous one are not always the same. Our pharmacy buying playbook covers financing and licensing in full, and the due diligence checklist is the cheapest money you will spend on the transaction.

Related Guides